» Articles » PMID: 33158279

Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Nov 7
PMID 33158279
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most prevalent malignancy of the endocrine system and the ninth most common cancer globally. Despite the advances in the management of thyroid cancer, there are critical issues with the diagnosis and treatment of thyroid cancer that result in the poor overall survival of undifferentiated and metastatic thyroid cancer patients. Recent studies have revealed the role of different non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) that are dysregulated during thyroid cancer development or the acquisition of resistance to therapeutics, and may play key roles in treatment failure and poor prognosis of the thyroid cancer patients. Here, we systematically review the emerging roles and molecular mechanisms of ncRNAs that regulate thyroid tumorigenesis and drug response. We then propose the potential clinical implications of ncRNAs as novel diagnostic and prognostic biomarkers for thyroid cancer.

Citing Articles

The role of genetic and epigenetic modifications as potential biomarkers in the diagnosis and prognosis of thyroid cancer.

Sabi E Front Oncol. 2024; 14:1474267.

PMID: 39558949 PMC: 11570407. DOI: 10.3389/fonc.2024.1474267.


Pan-Cancer Analysis Reveals Long Non-coding RNA (lncRNA) Embryonic Stem Cell-Related Gene (ESRG) as a Promising Diagnostic and Prognostic Biomarker.

Fageer S, Alamin M, Attaelmanan A, Alfaki M Cureus. 2024; 16(8):e67389.

PMID: 39310490 PMC: 11414139. DOI: 10.7759/cureus.67389.


BRAFV600E, BANCR, miR-203a-3p and miR-204-3p in Risk Stratification of PTC Patients.

Stojanovic S, Selemetjev S, doric I, Miljus J, Tatic S, Zivaljevic V Biomedicines. 2023; 11(12).

PMID: 38137560 PMC: 10742276. DOI: 10.3390/biomedicines11123338.


Dioscin Impedes Proliferation, Metastasis and Enhances Autophagy of Gastric Cancer Cells via Regulating the USP8/TGM2 Pathway.

Ma T, Ge X, Zhu J, Song C, Wang P, Cai J Mol Biotechnol. 2023; 66(12):3700-3711.

PMID: 38085503 DOI: 10.1007/s12033-023-00978-7.


Interactions between circRNAs and miR-141 in Cancer: From Pathogenesis to Diagnosis and Therapy.

Guz M, Jeleniewicz W, Cybulski M Int J Mol Sci. 2023; 24(14).

PMID: 37511619 PMC: 10380543. DOI: 10.3390/ijms241411861.


References
1.
Yang J, Schnadig V, Logrono R, Wasserman P . Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007; 111(5):306-15. DOI: 10.1002/cncr.22955. View

2.
Sistrunk J, Shifrin A, Frager M, Bardales R, Thomas J, Fishman N . Clinical impact of testing for mutations and microRNAs in thyroid nodules. Diagn Cytopathol. 2019; 47(8):758-764. PMC: 6766884. DOI: 10.1002/dc.24190. View

3.
Jung Y, Park J . Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020; 52(2):183-191. PMC: 7062731. DOI: 10.1038/s12276-020-0380-6. View

4.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

5.
Pishkari S, Paryan M, Hashemi M, Baldini E, Mohammadi-Yeganeh S . The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J Endocrinol Invest. 2017; 41(3):269-283. DOI: 10.1007/s40618-017-0735-6. View